OTS964   Click here for help

GtoPdb Ligand ID: 7813

PDB Ligand
Compound class: Synthetic organic
Comment: OTS964 is a potent and selective inhibitor of the PDZ binding kinase, PBK (aka TOPK) [2]. The compound is undergoing pre-clinical assessment.
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 2
Hydrogen bond donors 2
Rotatable bonds 4
Topological polar surface area 84.57
Molecular weight 392.16
XLogP 4.91
No. Lipinski's rules broken 0
SMILES / InChI / InChIKey
Click here for help
Canonical SMILES CN(CC(c1ccc(cc1)c1c(O)cc(c2c1c1ccsc1c(=O)[nH]2)C)C)C
Isomeric SMILES CN(C[C@@H](c1ccc(cc1)c1c(O)cc(c2c1c1ccsc1c(=O)[nH]2)C)C)C
InChI InChI=1S/C23H24N2O2S/c1-13-11-18(26)19(16-7-5-15(6-8-16)14(2)12-25(3)4)20-17-9-10-28-22(17)23(27)24-21(13)20/h5-11,14,26H,12H2,1-4H3,(H,24,27)/t14-/m0/s1
InChI Key XCFRUAOZMVFDPQ-AWEZNQCLSA-N
No information available.
Mechanism Of Action and Pharmacodynamic Effects Click here for help
PBK is a Ser/Thr protein kinase. This enzyme is aberrantly over-expressed in several human cancers, including those of the breast and lung [3-4,6]. PBK has been suggested as a novel target in the search for treatments for cancers such as triple-negative breast cancer and drug-resistant cancers which do not respond to current estrogen receptor or EGF receptor HER2) targeting anti-cancer therapies. In addition to being upregulated in triple-negative breast cancers and being correlated with poor prognosis in these patients [1], PBK is also required for cancer cell mitosis [5] and is not expressed in vital organs. All of these factors support PBK as a potential molecular target for future cancer treatments.